Get the Stockscreener App
0.0412
142.22%
0.0242
Galera Therapeutics Inc stock is traded at $0.0412, with a volume of 109.
It is up +142.22% in the last 24 hours and up +142.22% over the past month.
See More
Previous Close:
$0.017
Open:
$0.041178
24h Volume:
109
Relative Volume:
0.10
Market Cap:
$N/A
Revenue:
-
Net Income/Loss:
$-69.68M
P/E Ratio:
-0.0218
EPS:
-1.89
Net Cash Flow:
$-48.93M
1W Performance:
+142.22%
1M Performance:
+142.22%
6M Performance:
+142.22%
1Y Performance:
-96.95%
1-Day Range:
$0.0412
$0.0412
1-Week Range:
$0.0412
$0.0412
52-Week Range:
$0.017
$0.0412
Galera Therapeutics Inc Stock (GRTX) Company Profile
Name
Galera Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Compare GRTX vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRTX
Galera Therapeutics Inc
|
0.0412 | 0 | 0 | -69.68M | -48.93M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.17 | 117.08B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.03 | 82.63B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
742.79 | 45.82B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.38 | 42.92B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
305.39 | 33.54B | 5.36B | 287.73M | 924.18M | 2.5229 |
Galera Therapeutics Inc Stock (GRTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-10-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Oct-19-21 | Downgrade | BTIG Research | Buy → Neutral |
| Oct-19-21 | Downgrade | BofA Securities | Buy → Underperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-16-20 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-07-20 | Initiated | H.C. Wainwright | Buy |
| Dec-02-19 | Initiated | BTIG Research | Buy |
| Dec-02-19 | Initiated | BofA/Merrill | Buy |
| Dec-02-19 | Initiated | Citigroup | Buy |
| Dec-02-19 | Initiated | Credit Suisse | Neutral |
View All
Galera Therapeutics Inc Stock (GRTX) Latest News
Galera Therapeutics Sells Dismutase Mimetics Portfolio to Biossil in $108.5 Million Deal - MSN
GRTX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Galera Therapeutics Updates Preferred Stock Conversion Provisions - TipRanks
Galera Therapeutics (GRTX) grants board discretion on Series B conversion - Stock Titan
Galera Therapeutics Grants Retention Bonus to Key Officer - TipRanks
Doylestown’s Aprea Therapeutics Names Industry Veteran as Chief Medical Advisor - BUCKSCO.Today
Aprea Therapeutics, Inc. Appoints Eugene Kennedy as Chief Medical Advisor - marketscreener.com
Galera Therapeutics completes acquisition of Nova Pharmaceuticals - Intellectia AI
Malvern-based Galera Therapeutics Secures New Lease on Life with Acquirement Underway - MSN
Head to Head Analysis: Lite Strategy (NASDAQ:LITS) and Galera Therapeutics (NASDAQ:GRTX) - Defense World
GRTX (Galera Therapeutics) EV-to-OCF : 0.32 (As of Dec. 19, 2025) - GuruFocus
Chmn Sorensen Sells 70,000 ($1.4K) Of Galera Therapeutics Inc [GRTX] - TradingView
GRTX Form 4: CEO Sorensen reports 70,000-share stock sale - Stock Titan
Chmn Sorensen Files To Sell 70,000 Of Galera Therapeutics Inc [GRTX] - TradingView — Track All Markets
Galera Therapeutics, Inc. SEC 10-Q Report - TradingView
Galera Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] Galera Therapeutics, Inc. Quarterly Earnings Report | GRTX SEC FilingForm 10-Q - Stock Titan
Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D - Citeline News & Insights
Aprea Therapeutics Reports Early Signs of Activity in APR-1051 Cancer Trial - MyChesCo
Canadian company purchases Galera Therapeutics’ dismutase mimetics portfolio - Pennsylvania Business Report -
Galera Therapeutics Sells Assets to Biossil Inc. - TipRanks
Biossil to acquire Galera’s dismutase mimetics portfolio for up to $105M - MSN
Galera Therapeutics Acquires Dismutase Mimetics Portfolio by Biossil For $105 Million - citybiz
Galera Therapeutics (GRTX) Sells Asset Portfolio to Biossil - GuruFocus
Galera Therapeutics Announces Acquisition of Dismutase Mimetics Portfolio by Toronto-based Biossil for up to $105 Million - Yahoo Finance
Malvern firm selling drug portfolio in potential $105M deal after FDA setback - The Business Journals
Today's SEC FilingsLatest 10-K, 10-Q, 8-K Forms - Stock Titan
Oral Mucositis Market Size & Share | Industry Report, 2033 - Grand View Research
NanoCell Therapeutics Expands Scientific Advisory Board With Global Experts in Gene Therapy and Clinical Development - MyChesCo
Avasopasem manganese treatment for severe oral mucositis from chemoradiotherapy for locally advanced head and neck cancer: phase 3 randomized controlled trial (ROMAN) - The Lancet
Legend Biotech CorporationAmerican Depositary Shares (NQ: - FinancialContent
Galera Therapeutics Amends Royalty Agreement with Clarus - The Globe and Mail
Radiation-Induced Oral Mucositis in Head and Neck Cancer Market is expected to reach USD 1.63 billion by 2034 - openPR.com
Oral Mucositis Market Growth, Trends, Consumer Demand and Key Opportunities - openPR.com
Triple-Negative Breast Cancer Market Gearing Up for Impressive Growth at a CAGR of 4.7% During the Forecast Period (2025-2034) | DelveInsight - Yahoo Finance
Windtree Therapeutics to Launch BNB Crypto Treasury Strategy in Groundbreaking $200 Million Deal - MyChesCo
Warrington’s Windtree Therapeutics Acquires Waste Management Company - BUCKSCO.Today
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments - GlobeNewswire
Oral Mucositis Market to Observe Stunning Growth During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Aviceda Therapeutics Appoints Ophthalmology Innovator and Industry Leader Dr. Emmett T. Cunningham, Jr. to Board of Directors - Business Wire
Galera Therapeutics Inc. (GRTX) reports earnings - qz.com
Chemotherapy Oral Mucositis Market Trends 2025-2035 - Future Market Insights
Galera Therapeutics holds annual stockholder meeting - Investing.com
Pharmacological ascorbate combined with rucosopasem selectively radio-chemo-sensitizes NSCLC via generation of H - ScienceDirect.com
Oral Mucositis Treatment Market Size to Hit USD 3.72 Billion by 2034 - Precedence Research
Festive biotech M&A spree sees Poolbeg combine with Hookipa, while Vincerx braces for layoffs - Fierce Biotech
Galera Therapeutics sidesteps liquidation, acquires New York biotech company - The Business Journals
Radiation Induced Esophagitis Market Set to Grow Substantially Through 2032, DelveInsight Projects | Galera Therapeutics - The Globe and Mail
The 2024 Biotech Graveyard - Fierce Biotech
Oral Mucositis Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix - Barchart.com
Galera stockholders reject liquidation plan - Investing.com
Galera Therapeutics Inc Stock (GRTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.28%
17.88%
Cap:
|
Volume (24h):